

# Therapies to Combat Co-Infection of HIV and Malaria during Pregnancy in Sub-Saharan Africa

Michaela L Barker<sup>1</sup> and Andrew W Taylor-Robinson<sup>1,2\*</sup>

<sup>1</sup>School of Molecular & Cellular Biology, University of Leeds, UK

<sup>2</sup>School of Medical & Applied Sciences, Central Queensland University, Australia

**Corresponding author:** Andrew W Taylor-Robinson, Infectious Diseases Research Group, School of Medical & Applied Sciences, Central Queensland University, Rockhampton, QLD 4702, Australia, Tel: +61 7 4923 2008; **E-mail:** [a.taylor-robinson@cqu.edu.au](mailto:a.taylor-robinson@cqu.edu.au)

**Received date:** 15 Apr 2016; **Accepted date:** 07 May 2016; **Published date:** 12 May 2016.

**Citation:** Barker ML, Taylor-Robinson AW (2016) Therapies to Combat Co-Infection of HIV and Malaria during Pregnancy in Sub-Saharan Africa. *Int J Vaccine Immunizat* 2(2): doi <http://dx.doi.org/10.16966/2470-9948.111>

**Copyright:** © 2016 Barker ML, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

In sub-Saharan Africa where *Plasmodium falciparum* malaria is endemic, 80% of the world's HIV-infected persons reside, making co-infection with these two major human pathogens a common occurrence. Pregnancy is a condition that produces an immunosuppressed state in the mother, which, in combination with an immune compromising disease such as HIV/AIDS, can lead to an increased risk of contracting infectious diseases such as malaria. Co-infection during pregnancy can lead to a number of poor outcomes for both mother and child. There has been little research into the implications of pregnancy and/or co-infection with regard to treatment of HIV/AIDS or malaria, and as a result the options for efficacious drug therapy during gestation are limited. In light of this, prophylactic measures are being investigated, including a vaccine for pregnant women or those planning a family that aims to reduce or prevent the adverse effects of malaria and/or HIV/AIDS. This review discusses the pressing need for treatment, outlines the incumbent difficulties in production of an effective chemotherapeutic or immunization regimen, and considers strategies for present and prospective vaccine development.

**Keywords:** Malaria; *Plasmodium falciparum*; HIV; AIDS; Co-infection; Pregnancy; Placenta; Chemotherapy; Vaccine

## Introduction

Acquired immunodeficiency syndrome (AIDS), caused by the human immunodeficiency virus (HIV), and malignant malaria, caused by the protozoan parasite *Plasmodium falciparum*, are two of sub-Saharan Africa's greatest medical challenges with regard to both morbidity and mortality. Of the 36.9 million people infected with HIV/AIDS worldwide at the end of 2014, the most recent year for which statistics are available, 70% live in sub-Saharan Africa, equating to approximately 25.8 million infected individuals out of a population of 949 million [1-3]. Women account for 59% of HIV-infected people in sub-Saharan Africa, creating the potential for around 15.2 million women to have HIV infection during pregnancy [1]. *P. falciparum* causes between 149-303 million clinical episodes of malaria per year, of which 88% occur in sub-Saharan Africa [4]. The chances of a woman developing malaria during pregnancy are high, but what are the implications of co-existing HIV/AIDS during this period? This review examines the interactions of these two infections and their implications on pregnancy outcome, and assesses current treatments and future prospects for vaccine therapy to eliminate the potential threats posed by both of the major human diseases.

## Immunology of Pregnancy

The 'immunological paradox of pregnancy', the relationship between a mother and her semi-allogeneic foetus, remains a mystery since it was first recognized by Medawar in 1953. He proposed that foetal rejection does not occur due to lack of foetal antigen expression, either as a result of an anatomical separation between the mother and foetus or due to maternal lymphocyte suppression [5]. Research has since shown that there is no physical separation between the mother and foetus, rather that intimate contact occurs between various foetal cells and maternal immune cells. However, no antigenic stimulation of maternal lymphocytes occurs since

foetal trophoblast cells do not express major histocompatibility complex Ia antigens that are required for allograft rejection in humans [6].

The peripheral immune response differs during pregnancy due to a shift in cytokine production towards a type 2 profile [including interleukin (IL)-4, -5, -9, -10 and -13] promoting humoral immunity, as type 1 cytokines [e.g. IL-2, tumour necrosis factor (TNF)- $\beta$  and interferon (IFN)- $\gamma$ ] that are involved in cellular immune responses, cause inhibition of embryonic and foetal development. While the cause is unknown explanations include the direct effect of pregnancy-related hormones, placental interference with cytokine production, and trophoblastic production of predominantly type 2 cytokines [6,7].

Although few studies have examined the role of the innate immune system during pregnancy, it is known that numbers and activity of natural killer cells are decreased [7]. Modified monocyte and granulocyte function has been observed through increased expression of some activation-associated adhesion molecules, indicating that these cells are functional during pregnancy [7]. Dendritic cells, the most potent of the antigen-presenting cells, are known to be involved in regulating cytokine balance during pregnancy but further research is required [7,8].

In summary, the innate immune system is active throughout pregnancy, compensating for the suppressed cellular immune response. During infection, immunological responses to bacterial pathogens remain intact, whereas protection is compromised against viruses and other intracellular pathogens that are more efficiently controlled by the cellular immune response, leading to increased susceptibility to diseases caused by such agents [6,7].

## Neonatal Immunology

*In utero*, the foetus is protected by the mother, both physically and by transfer across the placenta of immune factors. The foetus' own immune

system starts to develop in early gestation but by birth it is still incomplete. The level of immune maturity at birth is dependent on to what extent passive immunity has been transferred and also the gestational age of the neonate [8].

Table 1 compares the major components of the immune system of a neonate with that of an adult, illustrating great immaturity in some areas, thereby increasing susceptibility to infection. The placental transfer of maternal immunoglobulin (Ig)G provides extra immunological support at birth, at which time serum levels in the neonate are comparable to those of the mother. The half-life of IgG is 3-4 weeks, and since neonatal levels are negligible at birth and take up to a year to reach adult titers, there is a physiological trough between 3-6 months when there is a deficiency of antibodies as passive maternal IgG levels diminish [8].

Such deficits in neonate immunity may explain the heightened susceptibility to and increased severity of particular infections, such as those caused by *Listeria* and *Toxoplasma* [8].

### A Brief Introduction to HIV Infection

Since the first diagnosis of HIV in 1981 infection has reached pandemic proportions globally, to date close to 78 million people are known to have contracted HIV of whom around half, 39 million, have died from AIDS-related causes [9]. The virus itself does not kill the human host, but by severely compromising the immune system renders them susceptible to opportunistic infections. Once an HIV patient is infected with an opportunistic pathogen, such as listed in table 2, they are diagnosed as having AIDS [10].

HIV is a retrovirus characterized by the possession of the enzyme reverse transcriptase that is required for the process of replication of double-stranded DNA from single-stranded RNA [11]. A member of the lentivirus family there are at least two subtypes of virus, HIV-1 and HIV-2. HIV-1 is the more virulent strain and is the cause of most HIV infections worldwide. It is thought to have originated from the common chimpanzee, *Pan troglodytes*, found in Cameroon [12]. HIV-1 can be subdivided further into group M (major) subtypes, of which there are at least ten, denoted by the letters A-J, and group O (outlier) subtypes, which are found in Cameroon and are highly divergent from group M [11]. HIV-2 is confined mainly to West Africa and is thought to have originated from the sooty mangabey monkey, *Cercocebus atys* [13,14]. Both subtypes are spread via the exchange of bodily fluids, mainly through sexual intercourse, intravenous drug use or blood transfusion. Vertical transmission may occur *in utero*, during vaginal delivery or through breast-feeding [11,14].

The pathogenesis of HIV is based on the intimate relationship formed between the virus and the human immune system. HIV shows tropism principally for the CD4<sup>+</sup> cell surface receptor found on T lymphocytes into which it gains entry through an interaction between the CD4<sup>+</sup> receptor and its own matrix glycoprotein, gp120, with the aid of the host

Component	Immune development
B cells	Normal numbers but immature, i.e. CD5 <sup>+</sup>
Antibodies	IgM to proteins but not to carbohydrate antigens
Complement	Classical 90%, alternative 60% adult levels, C8 and C9 only 20% of adult levels
T cells	Higher numbers than in adults but immature
Cytokines	IL-2 production normal IFN-γ only 20% of adult levels Th2 cytokines very low
Activity	Cytotoxic T cells only 30-60% of adult levels Natural killer cell activity only 50% of adult levels

**Table 1:** Differences between the immune system of a neonate compared to that of an adult

Candidiasis of bronchi, trachea or lungs
Candidiasis, oesophageal
Cervical carcinoma, invasive
Coccidioidomycosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal (1-month duration)
Cytomegalovirus (CMV) disease (other than liver, spleen or nodes)
CMV retinitis (with loss of vision)
Encephalopathy, HIV-related
Herpes simplex, chronic ulcers (1-month duration); or bronchitis, pneumonitis or oesophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis; chronic intestinal (1-month duration)
Kaposi's sarcoma
Lymphoma, Burkitt's
Lymphoma, immunoblastic
Lymphoma (primary) of brain
<i>Mycobacterium avium</i> complex or <i>M. kansasii</i> , disseminated or extrapulmonary
<i>Mycobacterium tuberculosis</i> , any site
<i>Mycobacterium</i> , other species or unidentified species, disseminated or extrapulmonary
<i>Pneumocystis carinii</i> pneumonia
Pneumonia, recurrent
Progressive multifocal leucoencephalopathy
<i>Salmonella</i> septicaemia, recurrent
Toxoplasmosis of brain
Wasting syndrome, due to HIV

**Table 2:** AIDS-defining conditions

cell's chemokine co-receptors CCR5 and CXCR4 [11]. Resistance to HIV infection has been observed in people with mutations in the expression of CCR5 [11]. HIV gains access to CD4<sup>+</sup> T cells via dendritic cells, which transport the virus particles to lymph nodes [15].

Incubation of the virus usually takes 2-4 weeks after exposure, during which time the patient is asymptomatic and has negative serology. Seroconversion occurs around 6-8 weeks, sometimes causing non-specific illness. This is self-limiting and recovery is usually complete within 3 weeks, otherwise the person continues to be asymptomatic. During this acute period, a massive destruction of memory CD4<sup>+</sup> T cells initiates immune dysfunction [16]. Clinical latency then occurs, a variable but usually long time during which a rapid viral turnover produces 10<sup>10</sup> virions daily. Lymphocytes infected with HIV have a half-life of less than 2 days and as a result 1-2% of the total CD4<sup>+</sup> T cell population is destroyed each day. Initially, this is matched by a restorative turnover of CD4<sup>+</sup> T cells. However in time CD4<sup>+</sup> T cell production fails to compensate for the numbers destroyed, leading to a fall in CD4<sup>+</sup> T cell count and an increase in viral load, thus triggering symptomatic HIV infection. In this dysfunctional immunological state the patient may become susceptible to both standard and opportunistic pathogens, prompting the last stage of illness, full-blown AIDS [17].

Highly active anti-retroviral treatment (HAART) has had a positive impact on the lives of HIV patients to whom it is available, prolonging clinical latency by limiting viral replication and thus reducing viral load. This involves the prescription of at least three drugs, usually two nucleoside reverse transcriptase inhibitors (NRTIs) and a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a third NRTI [18]. This combination regimen maximizes the number of active sites available to therapy and limits the risk of development of resistance.

## Effect of HIV infection during pregnancy

There are concerns that pregnancy may accelerate the progression of HIV/AIDS, either due to suppression of cellular immunity that takes place during pregnancy or due to hormonal changes, but at present there is no conclusive research available [19]. There is more evidence to suggest that HIV adversely affects pregnancy, a systematic review concluding a 1.8-6 times greater risk of spontaneous abortion when the mother is HIV-1-positive [20]. Women with HIV infection are also at increased risk of suffering adverse obstetric events such as post-operative endometritis or maternal postpartum haemorrhage [19].

Mother-to-child transmission (MTCT) causes 80-90% of HIV infections in children. This mode of transmission includes *in utero*, intrapartum and via breast-feeding of the infant. The risk of transmission is multifactorial, depending on the mother's HIV viral load, mode of delivery of the neonate, and course of treatment where available [21].

## A Brief Introduction to Malaria

Malaria is a parasitic disease caused by *Plasmodium* species transmitted via the bite of a female *Anopheles* mosquito. There are five species that infect humans – *P. falciparum*, *P. vivax*, *P. ovale*, *P. malariae* and *P. knowlesi* – each distinguished by variations in life cycle stage morphology and sequence and severity of symptoms [22]. Although the global incidence of malaria has fallen in recent years, currently there are still around 300 million episodes of clinical malaria per annum, resulting in an estimated 440,000 fatalities. Sub-Saharan Africa accounts for 90% of deaths, with *P. falciparum* being the leading cause of mortality [4].

In the mosquito vector the parasite reproduces sexually in the midgut and then asexually in the body cavity, producing sporozoites. These infectious stages migrate to the salivary glands from where they are inoculated into a human host during the next blood feed. Following transfer, sporozoites home to the liver where they reproduce asexually within parenchymal cells forming schizonts containing merozoites, which are released into the peripheral circulation where they rapidly invade erythrocytes. Another asexual reproductive cycle occurs in the blood that leads to erythrocyte rupture and release of new merozoites typically every 46-48 hours for *P. falciparum*. A small minority of merozoites develop into immature male and female gametocytes, which are the only forms that can infect mosquitoes, taken up at a subsequent blood feed [22,23].

The clinical features of malaria include paroxysms of chills, fever and sweating, and anaemia, the extent of which is dependent on the species of parasite, *P. falciparum* causing the most severe manifestations [24]. Treatment is complicated by resistance of the parasite to available drugs and of the mosquito to insecticides, both of which are becoming increasingly widespread.

## Effect of malaria infection during pregnancy

*P. falciparum* infection poses a significant threat, not only to the mother but also to the foetus and neonate. Maternal mortality rates can be as high as 50% in some areas, which are higher than in non-pregnant women. The risk of malaria causing harm during pregnancy is dependent on the intensity of transmission, level of anti-parasite immunity acquired previously by the mother, and effectiveness of this immunity during pregnancy [25]. Pregnant women are usually most susceptible during the second and third trimester of pregnancy, and are more likely to be symptomatic than non-pregnant women, developing complications such as pulmonary oedema and hypoglycaemia [26]. Placental malaria, another clinical complication that occurs during pregnancy and which has a major impact on neonatal morbidity and mortality, involves inflammation caused by accumulation of asexual erythrocytic parasites in maternal blood spaces of the placenta [26,27].

Under conditions of stable transmission, primigravidae, and to a lesser extent secundigravidae, are most at risk of malaria infection, which is often asymptomatic. Maternal anaemia, which can be life-threatening, and placental parasitaemia are the principal effects of infection on the mother in these areas. The foetus may suffer intrauterine growth retardation (IUGR), leading to low birth weight (LBW) and thus increasing greatly the risk of mortality [28].

All women living in regions of low or unstable malaria transmission predominantly lack acquired immunity to infection and so, regardless of pregnancy history, are equally susceptible to infection. However, the risk of developing severe malaria is 2-3 times higher for pregnant women than for their non-pregnant counterparts. Adverse consequences for the mother remain similar to those in stable areas of transmission, whereas those for the pregnancy may include stillbirth, spontaneous abortion, LBW or congenital infection [29,30].

## Co-Infection of HIV and Malaria

It is evident that HIV and malaria each has many implications on pregnancy in its own right. Co-infection of these two diseases, without the complication of pregnancy, can lead to a variety of interactions, a few of which have been studied, but the mechanisms remain largely unknown. Several hypotheses have been proposed but the complexity of each disease in itself leads to unpredictable results. For example, the increased risk of acquiring malaria during HIV infection was thought to be as a result of diminished CD4<sup>+</sup> T cell numbers, as these cells are responsible for the maintenance of immunity to malaria, but several studies have shown this not to be the case [31,32]. Four hypothetical patterns of interaction may be described:

- I. If simultaneous infection of HIV and malaria occurs, rapid induction of a strong anti-HIV cellular immune responsiveness can halt virus development. It may be that this affects development of the malaria parasite and/or immune-mediated malaria pathology, and possibly impedes development of natural immunity to malaria [31,33].
- II. Co-infection interactions within a person infected previously with HIV may depend on the duration of pre-infection. In those infected with HIV recently, a scenario similar to that described in I) may occur. Asymptomatic chronically infected HIV-positive individuals have defects in antigen presentation and immune responses shift towards a Th2 response, resulting in a possible negative impact on anti-malarial immunity. In HIV-infected persons with diminished CD4<sup>+</sup> T cell counts, increased parasitaemia and number of clinical episodes are demonstrated [33].
- III. In individuals who acquire HIV infection after an episode of malaria, two differing potential interactions may result. If the preceding malaria infection was acquired recently, a similar scenario to I) may occur. Alternatively, if the malaria infection is chronic and is left untreated HIV co-infection may inhibit parasite development. This may act synergistically with any previously acquired anti-malarial immunity to inhibit parasitaemia [32,33].
- IV. Newly acquired HIV infection in those who suffer repeated malaria infections, and who develop partial anti-parasite immunity, may almost completely eradicate existing anti-malarial immunity, hence showing the importance of CD4<sup>+</sup> T cells in immunity against malaria [31,33].

Acute infection of malaria in HIV-positive individuals results in higher plasma viral loads, regardless of the fact that malaria stimulates production of chemokines, pro-inflammatory cytokines and counter-regulatory cytokines, all of which should aid the immune response. The increase in viral load correlates with an increase in the pro-inflammatory response to the malaria parasite, and activation of a systemic immune

response initiated by macrophages. However, for unknown reasons *in vitro* studies have contradicted these findings [32,33].

## Co-Infection in Pregnancy

### Effect of HIV-1 infection on pregnant women suffering from malaria infection

A summary of 11 studies demonstrates that HIV-infected pregnant women carry a consistently higher risk of malarial parasitaemia, which occurs both throughout pregnancy and at delivery. Parasite densities in these women are also higher in comparison to non-HIV-infected women. This inability to control malaria infection increases a woman's risk of developing clinical and placental malaria [34].

In the absence of HIV infection women undergoing their first or second pregnancy are at greater risk of malaria infection than are multigravid women. HIV-infected women, irrespective of the number of pregnancies, are all susceptible to the risks associated with malaria [35].

As both HIV and malaria can cause anaemia in pregnancy, a synergistic relationship may occur, demonstrated by the fact that dual infection has been shown to significantly increase the risk of pregnancy-associated anaemia. This is possibly due to an increase in duration of malaria infection during co-infection, as a consequence of higher parasite densities [29].

### Effect of malaria infection in HIV-1-positive pregnant women

In HIV-1-positive adults *P. falciparum* infection can lead to a transient increase in plasma viral load concentrations, but in part this may be reversed by successful anti-malarial treatment. The scale of increase appears to be less in pregnant women compared to adults with symptomatic malaria, although pregnant women are rarely symptomatic. The observed increase is regardless of HIV disease severity and state of CD4<sup>+</sup> immunosuppression [36].

Elevated expression of CCR5 on placental macrophages and foetal Hofbauer cells can occur as a result of placental malaria. The availability of CCR5, a major receptor required by HIV-1 virus particles to enter host cells, could lead to a rise in placental viral load and a subsequent increased risk of MTCT of HIV-1 infection. This is consistent with research demonstrating that the majority of HIV-1 virus isolates transmitted from mother to foetus are CCR5-trophic [37].

### Effect of co-infection on maternal and neonatal morbidity and mortality

Women suffering from both HIV and *P. falciparum* infections during pregnancy have an increased risk of developing clinical malaria, which is defined as documented fever or history of fever in conjunction with microscopically detected parasitaemia. As both diseases separately are known to cause anaemia, with dual infection there is a greater risk of having any anaemia (<11 g/dL) or moderate to severe anaemia (<8 g/dL), possibly due to synergistic activity leading to malaria infection of longer duration and increased parasitaemia [34]. While all pregnant women who are infected with *P. falciparum* are susceptible to the accompanying obstetrical complications posed by malaria infection alone, such as post-partum haemorrhage and puerperal sepsis, whether or not these risks are greater in dual infection is unknown.

In regard to the neonate, there is an increased risk of a poor birth outcome including LBW (<2500 g), premature birth, and IUGR in dual infection. It may be that LBW reflects the combined effect of shortened gestational age and IUGR. According to data from Malawi, dual infection raises the risk of post-neonatal mortality 3-8 fold compared to HIV infection alone, suggesting an increased risk of MTCT in these infants or an increased rate of progression from HIV to AIDS [38]. More recent evidence shows a decreased risk of post-neonatal mortality in women

with co-infection in comparison to HIV infection only, and this protective factor also corresponds with a reduced MTCT risk in co-infected women [34,35].

Interference of transfer of maternal antibodies to the foetus can occur as a result of HIV infection, causing pathological changes to the placenta. This includes antibodies to antigens such as the blood stage peptides merozoite surface protein 3 (MSP-3), apical membrane antigen 1 (AMA-1), variant surface antigens (VSAs), and the pre-erythrocytic stage circumsporozoite protein NANP-5. During a normal pregnancy, Ig transfer is an active process whereby maternal IgG is taken up by FcRN receptors on the syncytiotrophoblast. The mechanism by which this process is disrupted by HIV is currently unknown [34].

Several studies show increased risk of malaria and anaemia in infants born to women infected with malaria during pregnancy, especially during the first 6 months of life. Theories to explain this heightened risk include the possibility of immune sensitization *in utero* and the development of immunological tolerance. Less research has been performed on the effect of HIV co-infection on susceptibility to malaria in infancy but available information does not show any relationship between the two factors [35]. HIV infection during infancy as a result of MTCT places the baby at risk of severe anaemia [34].

### Increased incidence of malaria infection in HIV-positive pregnant women

The increased susceptibility of pregnant women to malaria alone is not well understood but it is thought to be related to modifications in systemic and placental immunological parameters. While few studies have considered the impact of HIV in this scenario, current evidence demonstrates the following:

- i) Cellular immune response – in HIV-positive pregnant women the production of IFN- $\gamma$  by intervillous blood mononuclear cells (IVBMC) implicated in protection against placental malaria is reduced in response to *P. falciparum* antigen stimulation. This is due to severe impairment of the IL-12 pathway, which is more pronounced in patients with low CD4 counts (<500 cells per  $\mu$ L) [39].
- ii) Humoral immune response – studies have shown a partial impairment of humoral immunity to malaria in HIV-positive pregnant women. This is in response to the pre-erythrocytic stage circumsporozoite protein (NANP-5), AMA-1 and VSAs expressed on infected erythrocytes that bind to chondroitin sulfate A, a key receptor for placental sequestration. Such impairment is greatest in women with more advanced HIV/AIDS and occurs across all gravidities, with or without malaria [34].

### Effect of maternal co-infection on the risk of mother-to-child transmission of malaria

This is an under-researched area, for malaria as a stand-alone disease but also its co-infection with HIV. It is common to find cord blood malarial infection at delivery but clinical infection in the neonate is rarely seen. Placental sequestration may prevent passage of Igs from mother to foetus, which may possibly lead to increased susceptibility of the neonate to diseases such as measles and streptococcal pneumonia [40]. Further investigation is required to establish the effect of co-infection on MTCT of malaria.

### Effect of maternal co-infection on the risk of MTCT of HIV

Placental malaria has been shown to have a variable effect on MTCT of HIV, and so it may not necessarily be a risk factor. Conflicting results may reflect the complex relationship between maternal immunity to malaria

that could either result in stimulation of HIV virus particle replication in the placenta, thereby increasing local viral load, or in potential control of both the severity of malarial infection and HIV replication. A slight imbalance of factors concerning the immune response can lead to either an increased risk of MTCT or a protective effect, as demonstrated in figure 1. There is evidence to suggest that infants born to mothers who at birth have high plasma concentrations of CC-chemokines and strong anti-HIV cytotoxic and suppressor T cell responses have a reduced risk of HIV-1 infection through MTCT [34,39].

## Current Means of Prevention of HIV/Malaria Infection during Pregnancy

### Prevention of HIV infection during pregnancy

Transmission of HIV should be preventable by sexual health education of women from an early age. In developing countries increasing access of women to antenatal clinics during pregnancy is an excellent source of contact with patients and provides a good teaching opportunity [40]. In the majority of cases, patients will have already been infected with HIV prior to pregnancy [19], in which case the priorities are to provide HIV testing and counselling, and to prevent MTCT (discussed below).

### Prevention of HIV transmission to the neonate

As mentioned previously, prevention of transmission of HIV to the neonate is achieved, where available, through the prescription of HAART to reduce plasma viral load to <1000 copies/ml. However, in the majority of areas where this treatment is needed, it is unavailable due to lack of resources and funding. If women in resource-poor settings do have access to treatment, this will involve a single 200 mg dose of nevirapine during labor for the mother and one dose of 2 mg/kg of nevirapine for the neonate within 72 hours of delivery. Evidence shows this regimen to reduce the risk of MTCT by approximately 50% [41].

The World Health Organization (WHO) estimates that breast-feeding is responsible for approximately 50% of all infections in children caused by MTCT [29]. In an ideal scenario, resources would be available to enable mothers to provide their child with formula milk and clean water supplies with which to prepare the formula. As this is not the case, many women in resource-poor settings face no alternative but to breast-feed their child. Exclusive breast-feeding, with rapid and early cessation at about 4 months of age, has a decreased risk of MTCT compared to mixed-fed infants [42].


### Prevention of malaria infection during pregnancy

It is recommended by the WHO that all HIV-positive pregnant women receive intermittent preventive treatment of malaria during pregnancy (IPTp), involving a single dose of sulfadoxine-pyrimethamine at least three times during the second and third trimesters of pregnancy, unless the woman is already receiving cotrimoxazole prophylaxis. In non-HIV-infected women, only two doses are required, but there is evidence to show that this is less efficacious in primigravid and secundigravid HIV-positive women. In many parts of Africa, women fear taking sulfadoxine-pyrimethamine due to perceived side effects and risk to their unborn child [40,43]. Education and treatment should be provided together as part of routine antenatal care in sub-Saharan Africa and other regions where malaria is endemic. Use of insecticide-treated nets is also recommended by the WHO, which not only protects the mother from malaria during pregnancy, but also the neonate after their birth [44,45].

## Vaccines as Potential Future Prophylactic Measures

### HIV vaccine

The generation of a vaccine for HIV has proved difficult due to the diverse genetic variability of the virus, and the fact that the host cells which it targets are essential to contain not only the HIV infection, but also any secondary infections. Any potential vaccine should target induction of both mucosal and systemic immunity in order to combat



all modes of transmission. It would also be required to stimulate both innate and cellular immune responses, and to generate high numbers of neutralizing antibody, thereby providing a broad spectrum of protection against all subtypes of HIV [46]. So far, several vaccine concepts, along with a variety of routes of administration and schedules of immunization, have been tested and these can be reviewed through databases created by the International AIDS Vaccine Initiative and the US National Institutes of Health Vaccine Research Center [47]. The concept of using classical vaccination approaches, such as live-attenuated preparations or a whole-inactivated virus, has been shown to have major limitations, so newer strategies have been the focus of ongoing vaccine development [47]. The following information describes current vaccine strategies being researched, some of which are not only being applied to HIV vaccine development, but also to other diseases.

**Recombinant envelope subunits:** Rather than to introduce the entire HIV virus particle, an envelope subunit can be used to provoke an immune response. In primate models, however, HIV surface glycoproteins such as gp120, gp140 and gp160 stimulate only a transient immune response that does not protect from infection with a virulent strain of simian immunodeficiency virus (SIV) [48].

The Tat protein (trans-activator of transcription) could provide a potential target for vaccine development as it is more conserved than envelope proteins, it is expressed soon after invasion of the host, and it is an essential component of the HIV life cycle. The Tat protein is produced by a small number of RNA transcripts that are created by incomplete transcription of HIV RNA due to a hairpin structure within the RNA. The Tat protein eliminates this structure through binding and phosphorylation of cellular factors. Vaccines based on this protein have demonstrated partially protection and are currently undergoing human clinical trials. It is thought that it may be harnessed both to control virus replication and to prevent onset of disease [49].

**Synthetic peptides:** This aspect of vaccine development has focused mainly on the V3 loop of the envelope glycoprotein gp120. The immunogen was well tolerated but it failed to invoke the desired response of inducing neutralizing antibodies [50].

**Live recombinant vectors:** Live attenuated viral or bacterial strains are used as a vector to carry genetic information encoding HIV antigens of interest. These vaccines are able to stimulate both cell-mediated and humoral immunity [48]. Details of vectors currently used in HIV vaccine development are described in table 3.

**Naked DNA:** Purified plasmid DNA carrying a gene encoding a specific HIV antigen under the control of a mammalian transcription promoter can be administered via either intramuscular or intradermal

immunization. This leads to expression of the antigen at the injection site, invoking mainly a Th1-type immune response. As a vaccination method for humans results have been poor, as only weak immune responses are induced compared to those elicited in animal trials [48].

**Prime-boost concept:** Priming with a nucleic acid vaccine or a viral vector followed by boosting with either another vector or a peptide vaccine has been demonstrated to produce stronger immune responses compared to when either vaccine is given alone. Over past decades many vaccine combinations have been tried, including vaccinia and recombinant envelope subunit, DNA and adenovirus, and adenovirus and canarypox, but so far none has produced satisfactory results in humans.

A current major concern with regard to the design of a vaccine is the hypervariability of HIV, which means that over time antigens may not remain constant and so cannot be included in candidate preparations, and also implies that there is a wide range of variants of HIV, for which it is difficult to provide complete protection with a single vaccine [47]. This diversity is in part a result of being subjected to significant immune pressure imposed by T cell reactivity, enabling HIV to evade given immune responses [51,52]. The potential use of conserved regions as targets for vaccination is also complicated by hypervariability, as HIV may be able to mutate to evade vaccine-induced immunity. Another issue to be resolved is a lack of neutralizing antibody response generated by HIV, through one of its many immune evasion mechanisms, rendering useless a vaccine that would usually take advantage of the production of neutralizing antibodies. Furthermore, there is a need to induce a range of immune responses to adequately prevent disease regardless of whether it is introduced by free virus particles or by virally infected cells. The highly restricted host specificity of HIV means that there is no ideal animal model in which to demonstrate HIV disease and to test candidate vaccine efficacy. Combining these problems with a lack of financial support from the private sector, which is best equipped to develop and manufacture vaccines, and the extended duration of clinical trials required, ensures that production of a successful vaccine will take considerably longer than desired [53]. Current major difficulties encountered on the path towards an efficacious HIV vaccine are outlined in table 4.

### Malaria vaccine

A slow accumulation of naturally acquired partial immunity to *P. falciparum* that is observed in residents of endemic areas provides the rationale for development of a malaria vaccine. However, after several decades of research an efficacious vaccine has still to be realized. Progress has been hampered, due partly to the large number of genes (over 5,200) present in the malarial genome that could possibly code for a protective antigen [54]. Many potential vaccine targets within the parasite life cycle are the subject of investigation, as outlined in table 5.

Vector	Results
Canarypox vector	This vector carries multiple antigens and in trials 25-30% of volunteers elicit CD8 <sup>+</sup> cell-mediated immune responses and 70% of volunteers elicit CD4 <sup>+</sup> helper T cell responses.
	When the env protein is added as an antigen, neutralizing antibody responses are elicited to T cell laboratory-adapted HIV isolates, not primary HIV isolates.
Adeno and adeno-associated vectors	The recombinant adenovirus type 5 (rAd5) vector has demonstrated the most robust and durable CD8 <sup>+</sup> cell-mediated responses of any HIV vaccine in Phase I and II clinical trials. Prior exposure to this vector stimulates high titre antibodies which significantly reduce the effect of the vaccine.
	The recombinant adeno-associated virus (AAV) vector has been shown to elicit cell-mediated and antibody immune responses, and to suppress viral load in monkeys challenged with SIV. This vaccine is now in clinical trials.
Modified Vaccinia virus Ankara (MVA)	Phase II trials have shown MVA vectors to be immunogenic and well tolerated, but the CD8 <sup>+</sup> response does not match that of the rAd5 vector.
Alphavirus	Venezuelan Equine Encephalitis (VEE), used as a designed replicon particle, has the advantage of being able to express the HIV gene inserted at high levels. With SIV antigens, cell-mediated and antibody immune responses have been elicited. This may be due to the propensity of the vector to target antigen-presenting cells.

**Table 3:** Vectors currently used in HIV vaccine development

Scientific obstacles	Logistical obstacles
Antigenic diversity and hypervariability of the virus	Insufficient political leadership
Transmission of the disease by mucosal route	Insufficient funding allocated to AIDS vaccines
Transmission of the virus by infected cells	Lack or insufficient coordinated approach
Resistance of wild type virus to seroneutralization	Regulatory authorities in developing countries
Integration of the virus genome into host cell chromosomes	Slow approval process
Latency of the virus in resting memory T cells	Standardization of assays and reagents
Rapid reemergence of the viral escape mutants in the host	Length of clinical trials, especially of efficacy trials
Downregulation of major histocompatibility class I antigens	

**Table 4:** Current challenges to HIV vaccine research and development

Target	Vaccine potential
Sporozoite transmission	Complete inhibition of sporozoites by anti-sporozoite antibodies that can decrease parasite motility and transmigration. Inhibition must be complete, as a single surviving sporozoite will cause eventual malaria infection.
Liver stage development	Irradiation or specific targeted gene deletion of parasites confers sterile protection against infection.
Erythrocytic development	Blockage of merozoites and neutralization of toxins released during short period between erythrocyte rupture and re-invasion.
Endothelial cytoadhesion	Prevention of cytoadhesion by antibodies, thought to reduce most fatal outcomes caused by malaria.
Placental sequestration	Antibodies from multigravid women can be used to protect women undergoing their first pregnancy from pregnancy-associated malaria.
Transmission to <i>Anopheles</i> mosquito	Reduced transmission to the mosquito through antibody-mediated immune responses to gametocytes and ookinetes.

**Table 5:** Potential targets in the malaria life cycle for vaccine development

The main approach to malaria vaccine design has been to target one of the developmental stages of the parasite; pre-erythrocytic, asexual blood (erythrocytic) and sexual stages [55]. These different targets, along with examples, are described below.

**Pre-Erythrocytic vaccines** – These aim to prevent establishment of clinical infection by protecting hepatocytes from invasion through production of specific antibodies [56].

- i) Circumsporozoite protein (CSP) vaccines – This is the most documented and advanced of the group, and involves use of the CSP that can be found on the surface of both the sporozoite and infected hepatocytes. The leading candidate vaccine, RTS,S, comprises virus-like particles consisting of the C-terminus of CSP of *P. falciparum* and hepatitis B surface antigen [57]. Phase I clinical studies showed protection in six out of seven volunteers challenged with malaria. Further studies of dose range indicated efficacy levels from 30% in single dose patients to 55% in triple dose patients, although each with a short half-life [54]. Another investigation showed 71% efficacy in the first nine weeks post-vaccination but followed by rapid deterioration of protection [58]. The efficacy of this vaccine is greatly affected by the adjuvant with which it is administered and its formulation [54].
- ii) DNA vaccines and live recombinant vaccines – These are also based on CSP, and involve the use of a vector (typically one of attenuated vaccinia virus Ankara strain, yellow fever virus, adenovirus, Sindbis virus, fowlpox virus or cold-adapted attenuated influenza virus). Some candidates have been used in prime-boost combinations [59]. Despite success with plasmid DNA vaccines in mouse models, in which promising humoral and cellular responses were noted, these effects have yet to be replicated in human volunteers [60]. A multiple-antigen DNA vaccine called MuStDO-5 has been designed that involves CSP, liver stage antigens 1 and 3, sporozoite surface protein 2 and exported protein 1, but again although it was shown to be safe and well tolerated in mice, there was no evidence of protection in human trials [61].

**Asexual blood stage vaccines** – These aims to prevent manifestations of pathology associated with disease, not infection *per se*, by inhibition of parasite invasion cycles [54].

- i) Merozoite surface protein 1 (MSP-1), MSP-2 and ring stage-infected erythrocyte surface antigen (RESA) combination – This vaccine, known as ‘combination B’, is the most developed of the asexual blood stage candidates, and trials have shown a reduction in parasite density of 62% in vaccinated volunteers [62]. A revised version is currently being developed to include the FC27 allele genotype of MSP-2, as well as the original 3D7 allele genotype, as this is increasing in prevalence [63,64].
- ii) MSP-1 and AMA-1, a fusion antigen consisting of the 19 kDa fragment of MSP-1 and the C terminal region of AMA-1, has been produced and shows good immunogenicity in a rabbit model. Phase I clinical trials have indicated the vaccine to be safe and immunogenic, and so there are plans for further development of this vaccine [65].
- iii) MSP-3, glutamate-rich protein (GLURP) and serine repeat antigen (SERA) – MSP-3 has been found to be a target of protective antibodies in immune adults, and as the basis of a vaccine, has been shown to be safe and to produce long-lasting antibodies displaying antibody-dependent cellular inhibition (ADCI) in mouse models [66]. GLURP is similar to MSP-3, and a vaccine based on this protein is currently undergoing phase I clinical trials [67]. SERA is the largest known malaria protein and accumulates in the parasitophorous vacuole of schizonts and trophozoites [68]. SERA-based vaccines have demonstrated induction of parasite killing activity and ADCI *in vitro* [69].
- iv) Erythrocyte protein 1 (PfEMP-1) is a highly variable *P. falciparum* protein that facilitates adhesion of infected erythrocytes to the chondroitin sulfate receptor expressed in the placenta during pregnancy. The longer half-life of IgG to VSAs, specifically PfVAR2CSA, indicates the feasibility of antibodies acquired during primigravida being sustained to protect against malaria infection

in subsequent pregnancies [70]. Initial studies of a vaccine based on such antigens have, however, thus far failed to show evidence of protective efficacy [71,72].

**Transmission-Blocking vaccines** – These aims to induce antibodies against sexual stage antigens, preventing the development of infectious sporozoites within mosquitoes [73]. In doing so, communities will be protected from infection, rather than people individually. Vaccines currently undergoing trials contain the *P. falciparum* ookinete surface antigens Pfs25 and Pfs28, or the *P. vivax* homologues of these antigens, Pvs25 and Pvs28, and a vaccine based on the latter two antigens has been shown to be safe and to demonstrate modest immunogenicity [73,74].

In regard to pregnancy, the natural build-up of immunity over successive pregnancies due to production of antibodies that recognize placental parasites and which prevent their binding to the placenta suggest the feasibility of developing a pregnancy-associated vaccine [25,75]. Serological studies indicate that a single or finite number of antigens may be required in order to elicit protective immunity based on the production of parasite-specific antibodies [76].

There are major obstacles to vaccine production, including the lack of predictive and reliable animal models, the lack of immunological correlates of protection and the intrinsic antigenic variability of malaria parasites [55]. However, further to sequencing of the *P. falciparum* genome recent advances in bioinformatics should accelerate vaccine development [77].

## Discussion

The complexity of co-infection of an individual with any two or more diseases has many implications with regard to all aspects of preventive and therapeutic medicine. Pregnancy itself may be described as a self-limiting condition in which immunological effects occur due to the presence of a foreign body. In the scenario of co-infection of HIV and malaria during pregnancy, there are negative impacts on maternal morbidity and mortality, and on the outcome of the pregnancy, but very little is known about how or why this occurs. This may be due in part to an incomplete understanding of human immune responses to each disease in its own right [31]. It is appreciated that research of these topics is not a straightforward task; for example, assessing the effect of malaria on MTCT of HIV can involve the use of AIDS patients, asymptomatic patients with normal or lowered CD4<sup>+</sup> T cell counts, or areas of stable or unstable malaria transmission, each variable affecting build-up of immunity. There are many factors that can influence outcomes, making it difficult for valid conclusions to be drawn.

Campaigns to improve sexual education in developing countries are starting to show benefits. The US President's Emergency Plan for AIDS Relief provides funds to lower income nations that have high rates of HIV transmission, coinciding with areas of intense malaria endemicity. It is arguable whether or not the ABC approach (abstinence, being faithful and using condoms) supported by this program has contributed actively to a decline in transmission but, regardless, any form of public health education should be viewed in a positive light [78]. Attendance at antenatal clinics provides an ideal forum at which to educate women about HIV and malaria transmission prevention and prophylaxis, to provide counseling and support, and to offer HIV testing and malaria screening [79]. In isolation, such incremental action on an individual level will not solve the massive challenges of HIV and malaria infections globally, but for an expectant mother it may make a real, potentially life-changing difference, for both her and her child.

Economics plays a key role regarding if, and over how long a time frame, investigations of new therapeutic agents and vaccines can be sustained. Considering financial arguments for and against research development against an ethical perspective, especially where HIV and

malaria are concerned, will always spark debate. In a sense, accessibility to money is able to control life and death for the majority of those who suffer from these major human diseases. The contribution of pharmaceutical companies to the overall funding of HIV vaccine development is modest, approximately 10% of total income [80]. This may be because of the poor commercial value of the market, in the sense that those whose need for treatment is greatest cannot afford it. Also, if a prophylactic vaccine for HIV or malaria did become available, the market for drugs in areas where this is administered would decrease significantly.

The existence of poor models for HIV research limits vaccine development as findings from animal studies should be extrapolated only with caution to infection of humans [81]. It would be considered unethical to test a vaccine in a human volunteer before an animal trial, but if results between the two do not correlate the validity of the use of animal models may be questioned. Also, potential use of therapeutic vaccines for both HIV and malaria in pregnancy is difficult to research, again due to lack of reliable animal models to demonstrate safety and immunogenicity [66,82]. A lack of research is apparent concerning drug therapy for both diseases during pregnancy, limiting treatment options for expectant mothers who are in an increased immuno compromised state and who thus have a greater need for medication.

## Conclusions

The impact of HIV and malaria infections is a continuing global public health challenge. Co-infection of these major human infectious diseases is thought to affect approximately one million pregnancies per year in sub-Saharan Africa. Despite this scenario, there is a lack of conclusive evidence regarding the implications of co-infection in a non-pregnant host, never mind a pregnant woman. It has only been over the last decade that interest in co-infection of the pregnant host has attracted significant attention. To date, knowledge of treatment in co-infection is not extensive, limiting current therapeutic options for these patients. Although a vaccine for both HIV and *P. falciparum* may be considered possible, either is unlikely to be achieved in the near future. A deeper insight into the interactions of anti-malarial and anti-retroviral drugs during pregnancy is required so that improved regimens can be used whilst the wait for a vaccine continues.

## Conflict of Interest

The authors declare that they have no competing issues of interest.

## References

1. Avert (2015) Global HIV and AIDS statistics. Avert, Sussex, UK.
2. PRB (2015) 2015 World population data sheet. Population Reference Bureau, Washington, DC, USA.
3. UNAIDS (2015) AIDS by the numbers 2015. United Nations AIDS Organization, Geneva, Switzerland.
4. WHO (2015) World Malaria Report 2015. WHO, Geneva, Switzerland.
5. Billingham RE, Brent L, Medawar PB (2010) 'Actively acquired tolerance' of foreign cells. 1953. *J Immunol* 184: 5-8.
6. Alecsandru D, Garcia-Velasco JA (2015) Immunology and human reproduction. *Curr Opin Obstet Gynecol* 27: 231-234.
7. Veenstra van Nieuwenhoven AL, Heineman MJ, Faas MM (2003) The immunology of successful pregnancy. *Hum Reprod Update* 9: 347-357.
8. Manyonda IT (2006) *The Immunology of Human Reproduction*. Taylor & Francis, Abingdon, UK.
9. amfAR (2016) *Statistics worldwide*. The American Foundation for AIDS Research, New York, USA.
10. WHO (2014) *Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations*. WHO, Geneva, Switzerland.



11. Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S (2010) HIV virology and pathogenetic mechanisms of infection: a brief overview. *Ann Ist Super Sanita* 46: 5-14.
12. Keele BF, van Heuverswyn F, Li Y, Bailes E, Takehisa J, et al. (2006) Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. *Science* 313: 523-526.
13. Reeves JD, Doms RW (2002) Human immunodeficiency virus type 2. *J Gen Virol* 83: 1253-1265.
14. De Cock KM (2001) Epidemiology and the emergence of human immunodeficiency virus and acquired immune deficiency syndrome. *Philos Trans R Soc Lond B Biol Sci* 356: 795-798.
15. Lekkerkerker AN, van Kooyk Y, Geijtenbeek TB (2006) Viral piracy: HIV-1 targets dendritic cells for transmission. *Curr HIV Res* 4: 169-176.
16. Derdeyn CA, Silvestri G (2005) Viral and host factors in the pathogenesis of HIV infection. *Curr Opin Immunol* 17: 366-373.
17. Picker LJ (2006) Immunopathogenesis of acute AIDS virus infection. *Curr Opin Immunol* 18: 399-405.
18. Ray S, Fatima Z, Saxena A (2010) Drugs for AIDS. *Mini Rev Med Chem* 10: 147-161.
19. El Beitune P, Duarte G, Quintana SM, Figueiró-Filho EA (2004) HIV-1: maternal prognosis. *Rev Hosp Clin Fac Med Sao Paulo* 59: 25-31.
20. Brocklehurst P, French R (1998) The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. *Br J Obstet Gynaecol* 105: 836-848.
21. Bongertz V (2001) Vertical human immunodeficiency virus type 1 – HIV-1 – transmission – a review. *Mem Inst Oswaldo Cruz* 96: 1-14.
22. Crompton PD, Moebius J, Portugal S, Waisberg M, Hart G, et al. (2014) Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease. *Annu Rev Immunol* 32: 157-187.
23. CDC (2016) Malaria Biology. Centers for Disease Control and Prevention, Georgia, USA.
24. CDC (2016) Malaria Disease. Centers for Disease Control and Prevention, Georgia, USA.
25. Ataíde R, Mayor A, Rogerson SJ (2014) Malaria, primigravidae, and antibodies: knowledge gained and future perspectives. *Trends Parasitol* 30: 85-94.
26. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, et al. (1998) Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. *Am J Trop Med Hyg* 59: 813-822.
27. Inion I, Mwanyumba F, Gaillard P, Chohan V, Verhofstede C, et al. (2003) Placental malaria and perinatal transmission of human immunodeficiency virus type 1. *J Infect Dis* 188: 1675-1678.
28. Alvarez JR, Al-Khan A, Apuzzio JJ (2005) Malaria in pregnancy. *Infect Dis Obstet Gynecol* 13: 229-236.
29. WHO (2005) Malaria and HIV interactions and their implications for public health policy. Report of a Technical Consultation, 23-25 June 2004. WHO, Geneva, Switzerland.
30. Moya-Alvarez V, Abellana R, Cot M (2014) Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. *Malar J* 13: 271.
31. Rénia L, Potter SM (2006) Co-infection of malaria with HIV: an immunological perspective. *Parasite Immunol* 28: 589-595.
32. Qadir MI, Maqbool F, Maqbool A, Ali M (2015) Review: HIV-*Plasmodium* co-infection: malaria in AIDS patients. *Pak J Pharm Sci* 28: 1811-1817.
33. Yartey JE (2006) Malaria in pregnancy: access to effective interventions in Africa. *Int J Gynaecol Obstet* 94: 364-373.
34. ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, et al. (2004) The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. *Am J Trop Med Hyg* 71: 41-54.
35. van Eijk AM, Ayisi JG, ter Kuile FO, Misore AO, Otieno JA, et al. (2003) HIV increases the risk of malaria in women of all gravidities in Kisumu, Kenya. *AIDS* 17: 595-603.
36. Mwapasa V, Rogerson SJ, Molyneux ME, Abrams ET, Kamwendo DD, et al. (2004) The effect of *Plasmodium falciparum* malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. *AIDS* 18: 1051-1059.
37. Tkachuk AN, Moormann AM, Poore JA, Rochford RA, Chensue SW et al. (2001) Malaria enhances expression of CC chemokine receptor 5 on placental macrophages. *J Infect Dis* 183: 967-972.
38. Bloland PB, Wirima JJ, Steketee RW, Chilima B, Hightower A, et al. (1995) Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. *AIDS* 9: 721-726.
39. Ned RM, Moore JM, Chaisavaneeyakorn S, Udhayakumar V (2005) Modulation of immune responses during HIV-malaria co-infection in pregnancy. *Trends Parasitol* 21: 284-291.
40. Vallely A, Vallely L, Chagalucha J, Greenwood B, Chandramohan D (2007) Intermittent preventative treatment for malaria in pregnancy in Africa: what's new, what's needed? *Malar J* 6: 16.
41. Reliquet V, Winer N, Chereau N, Launay E, Lamberet A, et al. (2014) The spectrum of HIV mother-to-child transmission risk. *J Int AIDS Soc* 17 (Suppl 3): 19703.
42. Menéndez C, D'Alessandro U, ter Kuile FO (2007) Reducing the burden of malaria in pregnancy by preventative strategies. *Lancet Infect Dis* 7: 126-135.
43. Mubyazi G, Bloch P, Kamugisha M, Kitua A, Ijumba J (2005) Intermittent preventive treatment of malaria during pregnancy: a qualitative study of knowledge, attitudes and practices of district health managers, antenatal care staff and pregnant women in Korogwe District, North-Eastern Tanzania. *Malar J* 4: 31.
44. WHO (2015) Guidelines for the Treatment of Malaria, 3<sup>rd</sup> edition. WHO, Geneva, Switzerland.
45. Brentlinger PE, Behrens CB, Micek MA (2006) Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. *Lancet Infect Dis* 6: 100-111.
46. Singh M (2006) No vaccine against HIV yet – are we not perfectly equipped? *Virol J* 3: 60.
47. Masoud M, Taylor-Robinson AW (2015) Prediction of epitopes of viral antigens recognized by cytotoxic T lymphocytes as an immunoinformatics approach to anti-HIV/AIDS vaccine design. *Int J Vaccines Vaccin* 1: 00014.
48. Sugimoto C, Watanabe S, Naruse T, Kajiwara E, Shiino T, et al. (2010) Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV. *PLoS One* 5: e11678.
49. Fanales-Belasio E, Cafaro A, Cara A, Negri DR, Fiorelli V, et al. (2002) HIV-1 Tat-based vaccines: from basic science to clinical trials. *DNA Cell Biol* 21: 599-610.
50. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL (2010) HIV vaccines: lessons learned and the way forward. *Curr Opin HIV AIDS* 5: 428-434.
51. Brander C, Frahm N, Walker BD (2006) The challenges of host and viral diversity in HIV vaccine design. *Curr Opin Immunol* 18: 430-437.
52. Lal RB, Chakrabarti S, Yang C (2005) Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy and vaccine development. *Indian J Med Res* 121: 287-314.

53. International AIDS Vaccine Initiative (2008) AIDS Vaccine Blueprint: A Challenge to the Field, a Roadmap for Progress. IAVI, New York, USA.
54. Girard MP, Reed ZH, Friede M, Kieny MP (2007) A review of human vaccine research and development: malaria. *Vaccine* 25: 1567-1580.
55. Taylor-Robinson AW (2014) Advancement towards an approved vaccine to target *Plasmodium falciparum* malaria. *Int J Immunol* 2: 31-39.
56. Doolan DL, Hoffman SL (2000) The complexity of protective immunity against liver-stage malaria. *J Immunol* 165: 1453-1462.
57. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, et al. (2001) Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental *Plasmodium falciparum* malaria. *J Infect Dis* 183: 640-647.
58. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Allouche A, et al. (2001) Efficacy of RTS,S/AS02 malaria vaccine against *Plasmodium falciparum* infection in semi-immune adult men in The Gambia: a randomised trial. *Lancet* 358: 1927-1934.
59. Matuschewski K (2006) Vaccine development against malaria. *Curr Opin Immunol* 18: 449-457.
60. Parker SE, Monteith D, Horton H, Hof R, Hernandez P, et al. (2001) Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. *Gene Ther* 8: 1011-1023.
61. Moore AC, Hill AVS (2004) Progress in DNA-based heterologous prime-boost immunization strategies for malaria. *Immunol Rev* 199: 126-143.
62. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, et al. (2002) A recombinant blood-stage malaria vaccine reduces *Plasmodium falciparum* density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. *J Infect Dis* 185: 820-827.
63. Flück C, Smith T, Beck HP, Irion A, Betuela I, et al. (2004) Strain-specific humoral response to a polymorphic malaria vaccine. *Infect Immun* 72: 6300-6305.
64. Zhang D, Pan W (2005) Evaluation of three *Pichia pastoris*-expressed *Plasmodium falciparum* merozoite proteins as a combination vaccine against infection with blood-stage parasites. *Infect Immun* 73: 6530-6536.
65. Pan W, Huang D, Zhang Q, Qu L, Zhang D, et al. (2004) Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth *in vitro*. *J Immunol* 172: 6167-6174.
66. Audran R, Cachat M, Lurati F, Soe S, Leroy O, et al. (2005) Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. *Infect Immun* 73: 8017-8026.
67. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, et al. (2000) Naturally acquired antibodies to the glutamate-rich protein are associated with protection against *Plasmodium falciparum* malaria. *J Infect Dis* 181: 1202-1205.
68. Li J, Mitamura T, Fox BA, Bzik DJ, Horii T (2002) Differential localization of processed fragments of *Plasmodium falciparum* serine repeat antigen and further processing of its N-terminal 47 kDa fragment. *Parasitol Int* 51: 343-352.
69. Pang XL, Mitamura T, Horii T (1999) Antibodies reactive with the N-terminal domain of *Plasmodium falciparum* serine repeat antigen inhibit cell proliferation by agglutinating merozoites and schizonts. *Infect Immun* 67: 1821-1827.
70. Fowkes FJI, McGready R, Cross NJ, Hommel M, Simpson JA, et al. (2012) New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. *J Infect Dis* 206: 1612-1621.
71. Smith JD, Deitsch K (2004) Pregnancy-associated malaria and the prospects for syndrome-specific antimalaria vaccines. *J Exp Med* 200: 1093-1097.
72. Kane EG, Taylor-Robinson AW (2011) Prospects and pitfalls of pregnancy-associated malaria vaccination based on the natural immune response to *Plasmodium falciparum* VAR2CSA-expressing parasites. *Malar Res Treat* 2011: 764845.
73. Peymanfar Y, Taylor-Robinson AW (2016) *Plasmodium* sexual stage parasites present distinct targets for malaria transmission-blocking vaccine design. *Int J Vaccine Immunizat* 2: 1-6.
74. Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, et al. (2000) Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of *Plasmodium vivax* to infect mosquitoes. *Infect Immun* 68: 6618-6623.
75. Morley LC, Taylor-Robinson AW (2012) Understanding how *Plasmodium falciparum* binds to the placenta and produces pathology provides a rationale for pregnancy-associated malaria vaccine development. *Open Vaccine J* 5: 8-27.
76. Duffy PE (2003) Maternal immunization and malaria in pregnancy. *Vaccine* 21: 3358-3361.
77. Florent I, Maréchal E, Gascuel O, Bréhélin L (2010) Bioinformatic strategies to provide functional clues to the unknown genes in *Plasmodium falciparum* genome. *Parasite* 17: 273-283.
78. Murphy EM, Greene ME, Mihailovic A, Olupot-Olupot P (2006) Was the "ABC" approach (abstinence, being faithful, using condoms) responsible for Uganda's decline in HIV? *PLoS Med* 3: e379.
79. Divala TH, Mungwira RG, Laufer MK (2015) Moving targets: The challenges of studying infectious diseases among pregnant women in resource limited settings. *Vaccine* 33: 6401-6405.
80. Vitoria M, Granich R, Gilks CF, Gunneberg C, Hosseini M, et al. (2009) The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. *Am J Clin Pathol* 131: 844-848.
81. Letvin NL (2006) Progress and obstacles in the development of an AIDS vaccine. *Nat Rev Immunol* 6: 930-939.
82. Clark DA (2016) Mouse is the new woman? Translational research in reproductive immunology. *Semin Immunopathol* 38: in press.